The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable anticipation within the industry. A shift away from Schedule I status, often considered as outdated and https://yourbookmarklist.com/story20935403/cannabinoid-rescheduling-a-expansion-catalyst